{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001055","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.588873+00:00","generated_at":"2026-05-18T09:42:21.828423+00:00","sec_items":["1.01","2.01","2.03","3.02","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Pelthos Therapeutics closes merger with LNHC, raises $50.1M PIPE","bullets":["Closed merger with LNHC (Ligand subsidiary) on July 1, 2025; LNHC shareholders own ~55.8% on fully diluted basis.","Raised ~$50.1M in PIPE financing via Series A Preferred Stock at $1,000/share; Ligand participated.","Effected 1-for-10 reverse stock split and changed name to Pelthos Therapeutics; ticker changes to PTHS on NYSE American.","Appointed Scott Plesha as CEO/President; Francis Knuettel remains CFO; added four new directors to board.","Entered royalty sale agreements for ZELSUVMI and other products with Nomis, Ligand, and Madison."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001055","json":"https://secwatch.observer/filing/0001753926-25-001055.json","markdown":"https://secwatch.observer/filing/0001753926-25-001055.md","text":"https://secwatch.observer/filing/0001753926-25-001055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/0001753926-25-001055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/g084856_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:42:21.828423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"626aadb57f7ec7b4ce5e51b56c189ad01d304c57","claim":"Pelthos Therapeutics Inc.: Company effected a reverse stock split at a 1:10 ratio effective July 1, 2025 (effective 2025-07-01).","evidence_excerpt":"the Company effected the Reverse Stock Split pursuant to the Reverse Stock Split Certificate of Amendment.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/0001753926-25-001055-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Effective","value":"2025-07-01"}],"fact_type":"governance_change"},{"claim_id":"6dab306ebf142a8d91d27826c9c75be0b1fd1b44","claim":"Pelthos Therapeutics Inc.: Company changed name from Channel Therapeutics Corporation to Pelthos Therapeutics, Inc.","evidence_excerpt":"the Company changed its name from “Channel Therapeutics Corporation” to “Pelthos Therapeutics, Inc.” pursuant to the Name Change Certificate of Amendment.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001055/0001753926-25-001055-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}